E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-Small Cell Lung Cancer. |
|
E.1.1.1 | Medical condition in easily understood language |
Lung cancer that has spread to areas near the lungs or other organs and has not yet been treated by chemotherapy. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029518 |
E.1.2 | Term | Non-small cell lung cancer stage II |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029520 |
E.1.2 | Term | Non-small cell lung cancer stage IIIA |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029521 |
E.1.2 | Term | Non-small cell lung cancer stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the safety of Atezo + Tira as neoadjuvant treatment followed by either Atezo + Tira or Chemo as adjuvant treatment; • To evaluate the safety of Atezo + Tira + Chemo as neoadjuvant treatment followed by Atezo + Tira as adjuvant treatment; • To evaluate the efficacy of Atezo + Tira or Atezo + Tira + Chemo as neoadjuvant treatment based on major pathological response (MPR) rate.
|
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the efficacy of Atezo + Tira or Atezo + Tira + Chemo as neoadjuvant treatment based on pathological complete response (pCR); • To evaluate the efficacy of Atezo + Tira as neoadjuvant treatment followed by either Atezo + Tira or Chemo as adjuvant treatment based on event free survival (EFS); • To evaluate the efficacy of Atezo + Tira + Chemo as neoadjuvant treatment followed by Atezo + Tira as adjuvant treatment based on EFS; • To characterize the PK profile of atezolizumab and tiragolumab when given in combination; • To evaluate the immune response to atezolizumab and tiragolumab.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology; • Eligible for R0 resection with curative intent at the time of screening, as confirmed by the operating attending surgeon and involved medical oncologist prior to study enrollment; • Adequate pulmonary function to be eligible for surgical resection; • Measurable disease, as assessed by the investigator per RECIST v1.1; • Adequate tumor tissue for PD-L1 assessment; • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; • Adequate hematologic and end-organ function; • Negative HIV test at screening; • Negative for active hepatitis B and hepatitis C at screening. |
|
E.4 | Principal exclusion criteria |
• NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or NSCLC not otherwise specified; • Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC; • Any prior therapy for lung cancer; • Active or history of autoimmune disease or immune deficiency; • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis; • NSCLC with an activating EGFR mutation or ALK fusion oncogene; • Known c-ros oncogene 1 (ROS1) rearrangement; • History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death; • Severe infection within 4 weeks prior to initiation of study treatment; • Treatment with investigational therapy within 42 days prior to initiation of study treatment; • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies; • Pregnant or lactating women. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Incidence and length of surgical delays, incidence of operative and post-operative complications, and/or number of surgical cancellations related to study treatment; 2. Incidence and severity of adverse events, with severity determined according to NCI CTCAE v5.0. The severity of cytokine release syndrome will be determined according to the ASTCT CRS Consensus Grading Scale; 3. MPR, defined as ≤10% residual viable tumor at the time of surgical resection, as assessed by the central pathology laboratory.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. pCR, defined as the absence of any viable tumor cells in both the primary tumor and all sampled lymph nodes at the time of surgical resection, as assessed by the central pathology laboratory; 2. EFS, defined as the time from first dose of study drug to any of the following events, whichever occurs first: disease progression that precludes surgical resection, as assessed by the investigator according to RECIST v1.1; or local or distant disease recurrence after surgery, including the occurrence of a new primary NSCLC; or death from any cause; 3. Serum concentrations of atezolizumab and tiragolumab at specified timepoints; 4. Prevalence of ADAs to tiragolumab at baseline and incidence of ADAs to tiragolumab during the study; 5. Prevalence of ADAs to atezolizumab at baseline and incidence of ADAs to atezolizumab during the study.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Within 30 days after Pre- Surgery Visit; 2. Up to 6 years; 3-5. Day 1 Cycle 1, 2, 3, 4, 5, 8, 12, 16, at treatment discontinuation visit.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Korea, Republic of |
United States |
Italy |
Poland |
Netherlands |
Spain |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |